Diquas - Santen Asia
Each mL contains 30mg of diquafosol sodium. This product should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality. Patients with a history of hypersensitivity to any of the ingredients of this product.
Diquafosol ophthalmic solution 3 %: a review of its use in ...
Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye.
Diquafosol - Wikipedia
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010. [1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt. Its mechanism of action involves agonism of the P2Y2 purinogenic receptor. [2]
2022年11月21日 · Santen launches the dry-eye treatment DIQUAS ® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus
Uses of Diquas - Vinmec
Diquas medicine is made in the form of eye drops, with the main ingredient being Diquafosol Sodium. It is used to treat dry eye associated with conjunctival epithelial disorders associated with tear abnormalities.
DIQUAS® EYE DROPS
Eye Drop (Water and Mucin Secretion). Dry Eye. Instill 1 drop a time, 6 times daily. Patients with a history of hypersensitivity to any of the ingredients of this product.
diagnosed with dry eye, associated with keratoconjuctival epithelium disorders that accompany lacrimal fluid abnormality. How Diquas-S works . This medicine improves keratoconjunctival epithelial disorder by promoting secretion of mucin and water as components of tears, thereby improving the tear film conditions. Before you use Diquas-S